Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.24 USD
+0.04 (1.25%)
Updated May 9, 2024 04:00 PM ET
After-Market: $3.24 0.00 (0.00%) 5:00 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 81 - 100 ( 120 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Interim Phase 1 Results Show CLR 131''s Activity in Pediatric Brain Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Consistently Robust Phase 2 CLR 131 Data in Triple-Class Refractory MM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
CLR 131 Detailed Phase 2a Data at AACR, Deep - Durable Response in LPL/WM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
2Q20: Over a Year of Cash Runway, Looking Forward to 2H20 Data Releases
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Catching Up with Management - Approaching Pivotal CLR 131 Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Pivotal Study Schedule Intact Despite the Pandemic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
No COVID-19 Clinical Trial Slowdowns, Cash Runway Into 1Q21, Reports 1Q20
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Undervalued in the Face of Robust Efficacy - Reports 4Q19, Cash Into 1Q21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
32nd Annual Conference: Jonathan Aschoff''s Biotechnology Track Overview
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
KOL Call Helps Clarify Development Paths for CLR131; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department